Directory of Stock Market Company
This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.
Search into NYSE and TSX
by quote, company name or key word
FOLD - Amicus Therapeutics Inc
Amicus Therapeutics, Inc., incorporated on February 4, 2002, is a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. The Company’s lead product candidate, Amigal (migalastat hydrochloride) for Fabry disease, is in Phase III development. Its other clinical stage pr","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"
Amicus Therapeutics Inc News
Amicus Therapeutics Added to NASDAQ Biotechnology Index
MarketWatch (press release) - May 21, 2012
MarketWatch (press release) - May 21, 2012
CRANBURY, NJ, May 21, 2012 (GlobeNewswire via COMTEX) -- Amicus Therapeutics (NASDAQ:FOLD) , a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that the Company was added to the NASDAQ ...
Canaccord Genuity Reaffirms Buy Rating on Amicus Therapeutics (FOLD)
Movie News Guide (blog) - May 14, 2012
Movie News Guide (blog) - May 14, 2012
Amicus Therapeutics (NASDAQ: FOLD)'s stock had its “buy” rating reaffirmed by research analysts at Canaccord Genuity in a report released on Friday.
Semi-Annual Changes to the NASDAQ Biotechnology Index
MarketWatch (press release) - May 14, 2012
MarketWatch (press release) - May 14, 2012
NEW YORK, May 14, 2012 (GlobeNewswire via COMTEX) -- The NASDAQ OMX Group, Inc. (NASDAQ:NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index(R) , which will become effective prior to market open on Monday, ...
Equities Research Analysts' Ratings Reiterations for May, 11st (AGM, ALR, AMCX ...
Junction Report - May 11, 2012
Junction Report - May 11, 2012
Federal Agricultural (NYSE: AGM) had its “buy” rating re-affirmed by analysts at Compass Point. Alere Inc (NYSE: ALR) had its “buy” rating re-affirmed by analysts at Canaccord Genuity.
Amicus Therapeutics Announces First Quarter 2012 Financial Results
GlobeNewsWire (press release) - May 10, 2012
GlobeNewsWire (press release) - May 10, 2012
CRANBURY, NJ, May 10, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced financial results for the first quarter ended March 31, ...
Canaccord Genuity Reiterates a 'Buy' on Amicus Therapeutics (FOLD); Encouraged ... - StreetInsider.com (subscription)
Amicus Therapeutics Announces First Quarter 2012 Financial Results
MarketWatch (press release) - May 10, 2012
Amicus Therapeutics Rating Increased to Overweight at JPMorgan Chase (FOLD) - Movie News Guide (blog)
MarketWatch (press release) - May 10, 2012
CRANBURY, NJ, May 10, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) , a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced financial results for the first quarter ended March 31 ...
Amicus Therapeutics, Inc. (FOLD) Tops Q1 EPS by 1c; Guides In-line - StreetInsider.com (subscription)Amicus Therapeutics Rating Increased to Overweight at JPMorgan Chase (FOLD) - Movie News Guide (blog)
Analysts' Upgrades for May, 8th (ASEI, BG, BMA, COF, CTSH, EA, EPAY, FOLD ...
Junction Report - May 8, 2012
Junction Report - May 8, 2012
American Science And Engineering Incorporated (NASDAQ: ASEI) was upgraded by analysts at Benchmark Co. from a “sell” rating to a “hold” rating.
UPDATE: J.P. Morgan Upgrades Amicus Therapeutics
Benzinga - May 8, 2012
Benzinga - May 8, 2012
By Delores Land According to a research report published this morning, JP Morgan has upgraded Amicus Therapeutics (NASDAQ: FOLD) from Neutral to Overweight.
Amicus Therapeutics to Announce First Quarter 2012 Financial Results on May 10 ...
MarketWatch (press release) - May 4, 2012
MarketWatch (press release) - May 4, 2012
CRANBURY, NJ, May 4, 2012 (GlobeNewswire via COMTEX) -- Amicus Therapeutics (NASDAQ:FOLD) , a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced a conference call and live audio webcast on ...
Amicus Therapeutics Inc Names William D. Baird, III Chief Financial Officer
Reuters Key Development - Apr 16, 2012
Reuters Key Development - Apr 16, 2012
NYSE Media Coverage Selection of the best articles found in your favorit medias